• breast cancer - HER2-positive
• es-BC - HER2 negative - (neo)adjuvant (NA) 1
• es-BC - HER2 positive - (neo)adjuvant (NA) 4
• la/mBC - HER2 positive
• la/mBC - HER2 positive - (neo)adjuvant (NA)
• la/mBC - HER2 positive - 1st Line (L1) 5
• la/mBC - HER2 positive - 2nd Line (L2) 13

 

• antibody–drug conjugate
• trastuzumab deruxtecan
• trastuzumab emtansine
• trastuzumab emtasine plus endocrine therapy
• HER inhibitor
• EGFR inhibitor
• afatinib based treatment
• afatinib plus vinorelbine
• HER2 inhibitor
• neratinib based treatment
• neratinib
• neratinib plus capecitabine
• pertuzumab based treatment
• pertuzumab plus trastuzumab
• pertuzumab plus trastuzumab plus docetaxel
• trastuzumab based treatment
• trastuzumab plus endocrine therapy
• trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel
• tucatinib based treatment
• tucatinib plus trastuzumab plus capecitabine
• TKI anti HER1/EGFR and HER2/neu
• lapatinib based treatment
• lapatinib
• lapatinib plus capecitabine
• lapatinib plus trastuzumab
• immune chekpoint inhibitors
• anti-PD-(L)1
• pembrolizumab based treatment
• pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide
• inetetamab plus vinorelbine
• target therapy
• margetuximab based treatment
• margetuximab plus chemotherapy
• VEGF(R) inhibitor
• bevacizumab based treatment
• bevacizumab plus trastuzumab plus docetaxel

• versus all
• vs antibody–drug conjugate
• vs trastuzumab emtansine
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs nucleoside analogues (pyrimidine/purine)
• vs capecitabine
• vs taxanes
• vs paclitaxel
• vs paclitaxel followed by doxorubicin plus cyclophosphamide
• vs vinca alkaloids
• vs vinorelbine
• vs Standard of Care (SoC)
• vs HER inhibitor
• vs HER2 inhibitor
• vs pertuzumab based treatment
• vs pertuzumab plus trastuzumab plus cyclophosphamide
• vs pertuzumab plus trastuzumab plus docetaxel
• vs trastuzumab based treatment
• vs trastuzumab
• vs trastuzumab plus capecitabine
• vs trastuzumab plus chemotherapy
• vs trastuzumab plus docetaxel
• vs trastuzumab plus endocrine therapy
• vs trastuzumab plus vinorelbine
• vs TKI anti HER1/EGFR and HER2/neu
• vs lapatinib based treatment
• vs lapatinib
• vs lapatinib plus capecitabine
• vs lapatinib plus epirubicin and cyclophosphamide followed by docetaxel
• vs non active control
• vs placebo

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Comparator:  vs lapatinib plus epirubicin and cyclophosphamide followed by docetaxel;   vs trastuzumab;   vs trastuzumab plus docetaxel;   vs trastuzumab plus chemotherapy;   vs placebo;   vs lapatinib plus capecitabine;   vs trastuzumab plus capecitabine; 
Risk of bias:  low;   some concerns;   high;  NA;